Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
- PMID: 2860972
- DOI: 10.1016/s0092-8674(85)80050-7
Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
Abstract
Exposure of neu-oncogene-transformed NIH 3T3 cells to monoclonal antibodies reactive with the neu gene product, p185, results in the rapid and reversible loss of both cell-surface and total cellular p185. Although not directly cytotoxic, monoclonal anti-p185 antibody treatment causes neu-transformed NIH 3T3 cells to revert to a nontransformed phenotype, as determined by anchorage-independent growth. Isotype matched control antibodies of an unrelated specificity do not affect p185 levels or colony formation in soft agar by neu-transformed NIH 3T3 cells. Soft agar colony formation by NIH 3T3 cells transformed by ras oncogenes is not affected by anti-p185 antibody treatment. Anchorage-independent growth of cells from the ethylnitrosourea-induced rat neuroblastoma line in which neu was originally detected by DNA transfection is also inhibited in the presence of anti-p185 monoclonal antibodies. Collectively, these results suggest that p185 is required to maintain transformation induced by the neu oncogene.
Similar articles
-
Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.Oncogene. 1988 Apr;2(4):387-94. Oncogene. 1988. PMID: 2896329
-
Downstream signal transduction defects that suppress transformation in two revertant cell lines expressing activated rat neu oncogene.J Biol Chem. 1993 Aug 25;268(24):18136-42. J Biol Chem. 1993. PMID: 7688739
-
Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A.Cancer Res. 1993 Dec 1;53(23):5784-90. Cancer Res. 1993. PMID: 7902209
-
The role of non-ras transforming genes in chemical carcinogenesis.Environ Health Perspect. 1991 Jun;93:33-40. doi: 10.1289/ehp.919333. Environ Health Perspect. 1991. PMID: 1685444 Free PMC article. Review.
-
Biological studies and potential therapeutic applications of monoclonal antibodies and small molecules reactive with the neu/c-erbB-2 protein.Cell Biophys. 1994;24-25:209-18. doi: 10.1007/BF02789231. Cell Biophys. 1994. PMID: 7736525 Review.
Cited by
-
Targeting erbB Pathways in Breast Cancer: Dual Kinase Inhibition for Brain Metastasis and Prevention of p185HER2/Neu Tumor Development.Breast Cancer (Dove Med Press). 2024 Oct 30;16:725-733. doi: 10.2147/BCTT.S490904. eCollection 2024. Breast Cancer (Dove Med Press). 2024. PMID: 39493351 Free PMC article.
-
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance.Nat Rev Clin Oncol. 2024 Nov;21(11):818-832. doi: 10.1038/s41571-024-00939-2. Epub 2024 Sep 13. Nat Rev Clin Oncol. 2024. PMID: 39271787 Review.
-
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.Nat Rev Clin Oncol. 2024 Mar;21(3):185-202. doi: 10.1038/s41571-023-00849-9. Epub 2024 Jan 8. Nat Rev Clin Oncol. 2024. PMID: 38191924 Review.
-
In Vivo Imaging of [60]Fullerene-Based Molecular Spherical Nucleic Acids by Positron Emission Tomography.Mol Pharm. 2023 Oct 2;20(10):5043-5051. doi: 10.1021/acs.molpharmaceut.3c00370. Epub 2023 Aug 2. Mol Pharm. 2023. PMID: 37531591 Free PMC article.
-
Targeting HER2-positive breast cancer: advances and future directions.Nat Rev Drug Discov. 2023 Feb;22(2):101-126. doi: 10.1038/s41573-022-00579-0. Epub 2022 Nov 7. Nat Rev Drug Discov. 2023. PMID: 36344672 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous